University of Oklahoma Health Sciences Center

Clinical Assistant Professor of Medicine (Voluntary)

Accomplish Health

Accomplish Health is the leading telehealth medical weight management practice. Our physician-led teams comprised of obesity-specialized clinicians and dietitians partner with health systems and employers to deliver best-in-class obesity and cardiometabolic care to the populations they serve.

Co-Founder & Chief Medical Officer

Medical Advisor

Elo Health

Member of Medical Advisory Board for Elo Health, a nutrition with precision start-up.

Cedars-Sinai

Masters Candidate

Joint Faculty Appointment in the Departments of Medicine and General Surgery at Cedars-Sinai. Founded the Weight Management Clinic at The Weight Loss Center at Cedars-Sinai.

Obesity Medicine Physician and Academic Internal Medicine

Academic Hospitalist 

Kennamer Fellow

Resident Doctor

Impossible Healthcare Podcast

Started by two physicians at Cedars-Sinai in Los Angeles, the Impossible Healthcare Podcast is a unique look into what is changing in healthcare. Join Dr. Sameer Berry & Dr. Michael Albert as they sit down with thought leaders to discuss the most pressing topics in healthcare.

Co Host

Novo Nordisk

Served on Digital Health Obesity Advisory Board
Served on Pipeline Scientific Advisory Council 
Served on GLP-1 Digital Ecosystem National Advisory Board

Medical Consultant 

Gelesis

Digital Opinion Leader Advisory Board Member

University of California, Los Angeles

Health Science Assistant Clinical Professor of Medicine 

The Cedars-Sinai Accelerator

I served as clinical medicine and digital health consultant for several start-ups participating in the Cedars-Sinai Accelerator.

Digital Health Mentor

AliveCor Inc.

Clinical Research Consultant

I am a physician reimagining obesity care in the US. I have expertise in lifestyle & cardiometabolic medicine, disease prevention, and obesity treatment. My interests include translating scientific evidence into practice. My experience includes building medical programs and scaling clinical solutions using tech-enabled platforms to address the growing cardiometabolic epidemics of the 21st century.

🚨 New CV outcomes signal: Semaglutide vs Tirzepatide
- - - 
A recent real-world study reports that semaglutide reduced the risk of 3-point MACE (heart attack, stroke, ACM) by 29% more than tirzepatide in people with obesity and established CVD—despite an average follow-up of only ~9 months. https://ow.ly/6Q9350WP92q

This raises some critical questions:
❓ Are we seeing molecule-specific benefits unique to semaglutide?
❓ Or is the effect primarily mediated by weight loss?

The early divergence of survival curves in the SELECT trial hinted at weight-independent cardioprotection. If true, semaglutide may offer distinct cardiovascular benefits beyond weight loss alone.

I’m not fully convinced yet—but this is further reinforcement that semaglutide is not just a weight-loss drug. It may be one of the first obesity therapies with robust, reproducible CV outcome benefits.

🧬 Obesity care is evolving. Are we ready to treat it as a true cardiovascular disease intervention?
#ObesityMedicine #GLP1 #CardiovascularHealth #Semaglutide #Tirzepatide

Michael Albert MD

Physician dedicated to reimagining obesity and sleep care in the US

No alternative text description for this image

Taplio

Michael Albert MD's Linkedin Analytics

's Best Posts (last 30 days)

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Michael Albert MD's Linkedin Analytics

's Best Posts .css-qqfgvy{font-size:var(--chakra-fontSizes-md);}(last 30 days)

Want to drive more opportunities from LinkedIn?

Michael Albert MD's Linkedin Analytics

's Best Posts (last 30 days)